|
Epithelioid hemangioendothelioma, malignant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fluorescence in situ hybridization analysis showed CAMTA1-WWTR1 fusions in 4/7 low-grade and 23/23 intermediate-grade EHE (P<0.001).
|
25353289 |
2015 |
|
Epithelioid hemangioendothelioma, malignant
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genetic characterization of several soft tissue tumour types that occur in the skin has resulted in the identification of diagnostically useful markers: ALK gene rearrangement with corresponding ALK protein expression by immunohistochemistry in epithelioid fibrous histiocytoma; the WWTR1-CAMTA1 fusion gene with CAMTA1 protein expression in epithelioid haemangioendothelioma; MYC amplification and overexpression in radiation-associated angiosarcoma; and EWSR1 gene rearrangement in cutaneous myoepithelial tumours.
|
26763770 |
2016 |
|
Epithelioid hemangioendothelioma, malignant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Instead, WWTR1-CAMTA1 and YAP1-TFE3 fusion genes are found in almost all cases of epithelioid haemangioendothelioma.
|
26050962 |
2015 |
|
Epithelioid hemangioendothelioma, malignant
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subsequent reverse transcription-polymerase chain reaction (RT-PCR) confirmed in three EHE the WWTR1-CAMTA1 fusion product.
|
21584898 |
2011 |
|
Epithelioid hemangioendothelioma, malignant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of the genetics of EHE is important because targeted therapies toward products of the specific WWTR1-CAMTA1 gene fusion may have an impact in the near future.
|
28855107 |
2018 |
|
Epithelioid hemangioendothelioma, malignant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The WWTR1 (protein is known as TAZ)-CAMTA1 (WC) fusion gene defines epithelioid hemangioendothelioma, a malignant vascular cancer.
|
25961935 |
2016 |
|
Epithelioid hemangioendothelioma, malignant
|
0.100 |
Biomarker
|
disease |
BEFREE |
A WWTR1-CAMTA1 fusion is present in most classic epithelioid hemangioendothelioma, regardless of their clinical behavior, suggesting that additional genetic abnormalities might be responsible in driving a more aggressive biology.
|
31537895 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
In recent years, many studies have reported upregulation or nuclear localization of YAP/TAZ in a number of human malignancies, such as breast cancer, melanoma, lung cancer, especially squamous cell carcinoma in different organs.
|
31360073 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Transcriptional co‑activator with PDZ‑binding motif (TAZ), also known as WW domain‑containing transcription regulator 1, serves an important role in the carcinogenesis and progression of breast cancer.
|
31081045 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that SRC proto-oncogene, nonreceptor tyrosine kinase (SRC) is an important driver of YAP/TAZ activity in human breast cancer and melanoma cells.
|
30559289 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer.
|
23566416 |
2013 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
The expression of WWP1, BAG3, and WWTR1 was significantly increased in breast cancer.
|
25417742 |
2015 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We investigated the involvement of Hippo-related pathways in bone metastasis from breast cancer, by evaluating E-cadherin expression downstream of WWdomain-containing oxidoreductase (Wwox) and transcriptional co-activator with PDZ-binding motif (TAZ).
|
22717556 |
2013 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Recently, TAZ has also been identified as a major component of the novel Hippo-LATS tumor suppressor pathway and to function as an oncogene in breast cancer.
|
21258416 |
2011 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
We show here it can identify both known (WWTR1) and novel (SHARPIN) BC metastasis genes.
|
26506596 |
2015 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Therefore, in this study, we determine that PI3K and YAP/TAZ interact to promote breast cancer cell transformation.<b>Implications:</b> This study provides the first evidence that the Hippo pathway effectors TAZ and YAP are critical mediators of PI3K-induced mammary tumorigenesis and synergistically function together with PI3K in transformation of mammary cells.
|
29545474 |
2018 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that SRC proto-oncogene, nonreceptor tyrosine kinase (SRC) is an important driver of YAP/TAZ activity in human breast cancer and melanoma cells.
|
30559289 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Transcriptional co‑activator with PDZ‑binding motif (TAZ), also known as WW domain‑containing transcription regulator 1, serves an important role in the carcinogenesis and progression of breast cancer.
|
31081045 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In recent years, many studies have reported upregulation or nuclear localization of YAP/TAZ in a number of human malignancies, such as breast cancer, melanoma, lung cancer, especially squamous cell carcinoma in different organs.
|
31360073 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
We show here it can identify both known (WWTR1) and novel (SHARPIN) BC metastasis genes.
|
26506596 |
2015 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The expression of WWP1, BAG3, and WWTR1 was significantly increased in breast cancer.
|
25417742 |
2015 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Therefore, in this study, we determine that PI3K and YAP/TAZ interact to promote breast cancer cell transformation.<b>Implications:</b> This study provides the first evidence that the Hippo pathway effectors TAZ and YAP are critical mediators of PI3K-induced mammary tumorigenesis and synergistically function together with PI3K in transformation of mammary cells.
|
29545474 |
2018 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Recently, TAZ has also been identified as a major component of the novel Hippo-LATS tumor suppressor pathway and to function as an oncogene in breast cancer.
|
21258416 |
2011 |
|
Breast Carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We investigated the involvement of Hippo-related pathways in bone metastasis from breast cancer, by evaluating E-cadherin expression downstream of WWdomain-containing oxidoreductase (Wwox) and transcriptional co-activator with PDZ-binding motif (TAZ).
|
22717556 |
2013 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer.
|
23566416 |
2013 |